非白血病性髓样肉瘤的临床特征和预后。

Clinical characteristics and prognosis of nonleukemic myeloid sarcoma.

机构信息

Department of Hematology and Bone Marrow Transplant Center (JH, XY, LL, JZHU, JZHANG, WX, JSHI, WZ, GW, JSUN, ZC, HH), The First Affiliated Hospital of Zhejiang University, Zhejiang, China; and Intensive Care Unit (LZ), The Sir Run Run Shaw Hospital of Zhejiang University, Zhejiang, China.

出版信息

Am J Med Sci. 2014 Jun;347(6):434-8. doi: 10.1097/MAJ.0b013e31829ca859.

DOI:10.1097/MAJ.0b013e31829ca859

PMID:23928547

Abstract

Myeloid sarcoma (MS) is an extramedullary mass that is composed of immature myeloid cells. The objectives of this study was to describe the frequency, clinical characteristics and the prognostic factors of patients with nonleukemic MS. Twenty-three cases of nonleukemic MS were recorded in the authors' institution between April 2006 and March 2012. Most of the patients received systemic antiacute myeloid leukemia chemotherapy and the overall response rate was 91.3%, and 56.5% patients experienced complete remission. The anticipated 3-year progression-free survival and overall survival rates are 23% and 41%, respectively. The prognostic impact of nonleukemic MS is unclear. The cytogenetic and molecular abnormalities of malignant cells may be the most important prognostic factor because these are not always available because of cost and technical reason. In this case, the remission state, Ki67 score of tumor cells and number and size of the lesions might act as independent prognostic factors; this finding requires further confirmation.

摘要

骨髓肉瘤（MS）是由未成熟髓细胞组成的髓外肿块。本研究的目的是描述非白血病性 MS 患者的频率、临床特征和预后因素。作者所在机构在 2006 年 4 月至 2012 年 3 月期间记录了 23 例非白血病性 MS。大多数患者接受了全身性抗急性髓性白血病化疗，总体缓解率为 91.3%，56.5%的患者达到完全缓解。预期 3 年无进展生存率和总生存率分别为 23%和 41%。非白血病性 MS 的预后影响尚不清楚。恶性细胞的细胞遗传学和分子异常可能是最重要的预后因素，因为由于成本和技术原因，这些并不总是可用的。在这种情况下，缓解状态、肿瘤细胞的 Ki67 评分以及病变的数量和大小可能是独立的预后因素；这一发现需要进一步证实。